Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTA0XPV)

DTT Name DNA polymerase beta (POLB)
Gene Name POLB
DTT Type
Clinical trial target
 [1]
UniProt ID
DPOLB_HUMAN
TTD ID
T06958
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 2.7.7.7
Sequence
MSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYPHKIKSGAEAK
KLPGVGTKIAEKIDEFLATGKLRKLEKIRQDDTSSSINFLTRVSGIGPSAARKFVDEGIK
TLEDLRKNEDKLNHHQRIGLKYFGDFEKRIPREEMLQMQDIVLNEVKKVDSEYIATVCGS
FRRGAESSGDMDVLLTHPSFTSESTKQPKLLHQVVEQLQKVHFITDTLSKGETKFMGVCQ
LPSKNDEKEYPHRRIDIRLIPKDQYYCGVLYFTGSDIFNKNMRAHALEKGFTINEYTIRP
LGVTGVAGEPLPVDSEKDIFDYIQWKYREPKDRSE
Function
Repair polymerase that plays a key role in base-excision repair. Has 5'-deoxyribose-5-phosphate lyase (dRP lyase) activity that removes the 5' sugar phosphate and also acts as a DNA polymerase that adds one nucleotide to the 3' end of the arising single-nucleotide gap. Conducts 'gap-filling' DNA synthesis in a stepwise distributive fashion rather than in a processive fashion as for other DNA polymerases.
KEGG Pathway
Base excision repair (hsa03410 )
Human T-cell leukemia virus 1 infection (hsa05166 )
Viral carcinogenesis (hsa05203 )
Reactome Pathway
Resolution of AP sites via the multiple-nucleotide patch replacement pathway (R-HSA-110373 )
Resolution of AP sites via the single-nucleotide replacement pathway (R-HSA-110381 )
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway (R-HSA-5649702 )
PCNA-Dependent Long Patch Base Excision Repair (R-HSA-5651801 )
Ub-specific processing proteases (R-HSA-5689880 )
Abasic sugar-phosphate removal via the single-nucleotide replacement pathway (R-HSA-73930 )
POLB-Dependent Long Patch Base Excision Repair (R-HSA-110362 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
FF-10502 DM72JE4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.